Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo loratadine

This article was originally published in The Tan Sheet

Executive Summary

Private labeler receives tentative approval for loratadine syrup 10 mg/10 mL (ANDA 75-725), FDA says March 12; Teva holds first-to-file status for delivery form (1"The Tan Sheet" Dec. 9, 2002, p. 4). Perrigo plans to ship loratadine/pseudoephedrine combination, manufactured by Andrx, in mid-June (2"The Tan Sheet" Feb. 24, 2003, In Brief)...

You may also be interested in...



Schering OTC Claritin Coupons Appearing In Newspapers Dec. 15

Schering-Plough is offering consumers free samples of Claritin through a new Web site that became operational shortly after the drug's OTC approval

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel